AI Ushers in a New Era of Prognosis Management... "Dr. Answer 3.0" Project Group Officially Launched

Led by Seoul St. Mary's and Severance Hospitals,
26 Institutions Join the Project
AI-Based Prognosis Management Services
to Be Developed for 10 Disease Categories

The leading domestic medical artificial intelligence (AI) project, "Dr. Answer," has evolved to the next stage. With the official launch of the "Dr. Answer 3.0" project group, promoted by the Ministry of Science and ICT and the National IT Industry Promotion Agency, a new wave of medical innovation is beginning, connecting AI to the post-treatment prognosis management of patients after hospital care.

On October 1 in Seoul, the Ministry of Science and ICT held the "Dr. Answer 3.0 Project Group Launch Ceremony," officially announcing the start of the project. The goal of this initiative is to enable AI to provide ongoing health management for patients even after they return to daily life following treatment, and to support immediate medical intervention by healthcare professionals in emergency situations.

Doctor conducting telemedicine. Photo by Asia Economy DB

"Dr. Answer 3.0" will run for four years, from 2025 to 2028, with a total budget of 6.3 billion won allocated for this year. Initially, the project targeted four diseases, including breast cancer, kidney cancer, and heart disease. However, with additional funding secured, the scope has expanded to include gastric cancer, colorectal cancer, and maternal diseases, resulting in the development of prognosis management services for a total of ten disease categories.

This initiative marks the third phase of the "Dr. Answer" project, which began in 2018. While versions 1.0 and 2.0 focused on supporting diagnosis and treatment by medical professionals, version 3.0 aims to establish a continuous care system that extends from hospital treatment to home-based management. The strategy also includes the development of lightweight solutions that combine AI with sensors and devices, as well as early-stage collaboration with the Ministry of Food and Drug Safety to expedite regulatory approval.

The project group structure, unveiled at the launch ceremony, is characterized by collaboration between major hospitals and companies. Seoul St. Mary's Hospital (Professor Kim Daejin) and Severance Hospital (Professor Kwon Jayoung) are leading the project, joined by ten medical institutions including Asan Medical Center, Seoul National University Bundang Hospital, and Gachon University Gil Medical Center, along with sixteen companies such as EZCaretech, Acryl, and AITRICS. The project group plans to ensure safety and reliability through cross-validation and to carry out the medical device regulatory approval process from the early stages.

Ryu Jemyoung, the Second Vice Minister of the Ministry of Science and ICT, stated, "Dr. Answer 3.0 is an AI-based innovation model that enables patients to receive continuous management and support even after discharge. It will serve as an important milestone toward building a society where everyone can equally benefit from AI."

This content was produced with the assistance of AI translation services.